<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04702841</url>
  </required_header>
  <id_info>
    <org_study_id>2019-ky012</org_study_id>
    <nct_id>NCT04702841</nct_id>
  </id_info>
  <brief_title>CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors</brief_title>
  <official_title>Clinical Application of Chimeric Antigen Receptor Modified γδ T Cells（CAR - γ δ T Cells） in Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study on the clinical application of chimeric antigen receptor modified γδ T cells&#xD;
      (CAR - γδ T cells) in relapsed and refractory CD7 Positive T cell-derived malignant&#xD;
      tumors.The main purpose of this study was to evaluate the efficacy of car - γ δ T cell&#xD;
      infusion in patients with relapsed and refractory CD7 Positive T cell-derived malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      γδT cells are known as &quot;a great candidate for car-t cells&quot;. Although they only account for 2%&#xD;
      - 5% of all T cells in our body, they are a natural killer.&#xD;
&#xD;
      CD7 is recognized as a sensitive marker of T-ALL, and its expression level on T-ALL cells is&#xD;
      opposite to CD3: compared with normal T cells, the expression level of CD7 on T-ALL cells is&#xD;
      significantly increased (P &lt; 0.001), while the expression level of CD3 on T-ALL cells is&#xD;
      significantly decreased (P &lt; 0.001). At the same time, CD7 expression is absent in about 10%&#xD;
      of normal T cells, and these CD7 negative T cells have the ability of normal T cells to&#xD;
      express cytokines. Therefore, CD7 has become a potential target for the treatment of T-ALL&#xD;
      because of its specificity and safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR 3</measure>
    <time_frame>three months after CAR-T cells infusion</time_frame>
    <description>3-month objective response rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>CAR</condition>
  <condition>Malignant Tumors</condition>
  <arm_group>
    <arm_group_label>CAR-γδT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion,iv,0.2-5 ×10^6/ kg,once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chimeric antigen receptor modified γδ T cells</intervention_name>
    <description>Dosage: the total dosage of reinfusion is 0.2-5 × 10^6 / kg, which is determined according to the body weight of the subject and the effective content of cell preparation.</description>
    <arm_group_label>CAR-γδT</arm_group_label>
    <other_name>CAR-γδT cell infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. the patients must be patients with relapsed or refractory CD7 Positive T cell-derived&#xD;
             malignancies, who have at least one course of standard regimen chemotherapy and one&#xD;
             course of salvage regimen chemotherapy and have poor effect;&#xD;
&#xD;
          2. Researchers believe that there is no other feasible and effective alternative&#xD;
             treatment, such as hematopoietic stem cell transplantation;&#xD;
&#xD;
          3. Patients should have indicators for detection or evaluation of disease, including&#xD;
             detection of minimal residual disease (MRD) by immunophenotyping, cytogenetics or PCR;&#xD;
&#xD;
          4. They are 14-70 years old, regardless of gender or race;&#xD;
&#xD;
          5. Physical condition: ECoG score 0-2;&#xD;
&#xD;
          6. Cardiac function: left ventricular ejection fraction greater than or equal to 40%;&#xD;
&#xD;
          7. The expected survival time was &gt; 12 weeks;&#xD;
&#xD;
          8. Serum creatinine (CR) ≤ 1.5 × ULN (upper limit of normal value), alanine&#xD;
             aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, total&#xD;
             bilirubin ≤ 1.5 × ULN;&#xD;
&#xD;
          9. Patients have self-knowledge ability and can sign informed consent;&#xD;
&#xD;
         10. The guardian of the child patient agreed to sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. pregnant or lactating women;&#xD;
&#xD;
          2. Uncontrolled infection;&#xD;
&#xD;
          3. Active HBV or HCV infection;&#xD;
&#xD;
          4. People living with HIV;&#xD;
&#xD;
          5. Less than 100 days after allogeneic hematopoietic stem cell transplantation;&#xD;
&#xD;
          6. Patients with acute GVHD or chronic GVHD after allogeneic hematopoietic&#xD;
             transplantation;&#xD;
&#xD;
          7. Patients receiving GVHD treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xingbing Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>No.1, Swan Lake Road, new administrative and Cultural District, Hefei City, Anhui Province</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xingbing Wang</last_name>
    <phone>13856007984</phone>
    <email>wangxingbing@ustc.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huimin Meng</last_name>
    <phone>0551-65728070</phone>
    <email>huimin.meng@persongen.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xingbing wang, doctor</last_name>
      <phone>+8613856007984</phone>
      <email>wangxingbing@ustc.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD7 Positive T-cell</keyword>
  <keyword>γδT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

